Becton, Dickinson and Company (BDX)
Becton Dickinson (BDX) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Cramer's Stop Trading: Becton Dickinson
CNBC's Jim Cramer explains why he is keeping an eye on shares of Becton Dickinson.
Becton Dickinson (BDX) Q2 Earnings Top Estimates
Becton Dickinson (BDX) came out with quarterly earnings of $3.35 per share, beating the Zacks Consensus Estimate of $3.28 per share. This compares to earnings of $3.17 per share a year ago.
Medical device maker Becton Dickinson cuts 2025 profit forecast on potential tariff hit
Medical device maker Becton Dickinson lowered its annual profit forecast on Thursday, in anticipation of a potential hit from U.S. President Donald Trump's tariffs, sending its shares down 5% in premarket trading.
BD Reports Second Quarter Fiscal 2025 Financial Results
Revenue of $5.3 billion increased 4.5% as reported, 6.0% currency-neutral and 0.9% organic GAAP and adjusted diluted EPS of $1.07 and $3.35, respectively Company updates full-year fiscal 2025 guidance and provides estimated tariff impact FRANKLIN LAKES, N.J., May 1, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025 second quarter, which ended March 31, 2025.
BD to Present at Bank of America Securities Health Care Conference
FRANKLIN LAKES, N.J. , April 30, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Bank of America Securities Health Care Conference on Tuesday, May 13, 2025 at 1:00 pm Eastern Time.
MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK
This earnings season so far has reflected a continued recovery in sales for companies within the Medical sector. Earnings have increased year over year, albeit at a slower pace than revenues.
BD Board Declares Dividend
FRANKLIN LAKES, N.J. , April 29, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.04 per common share, payable on June 30, 2025 to holders of record on June 9, 2025.
Can Sustained Product Demand Drive BDX Stock Before Q2 Earnings?
The continued solid uptake of BD's products is expected to have driven fiscal second-quarter revenues despite transitory market dynamics.
Gear Up for Becton Dickinson (BDX) Q2 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Becton Dickinson (BDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Becton, Dickinson and Company: It's Wait And See For Me
Becton, Dickinson and Company is a leading medical device firm specializing in medical supplies, devices, laboratory equipment, and diagnostic products. BDX operates in three segments: BD Medical, BD Life Sciences, and BD Interventional, with plans to spin off its Biosciences and Diagnostic Solutions business in 2026. BDX has struggled over the past decade, with a 10-year CAGR of only 5.1%.
BD Launches Industry-First Bioabsorbable Mesh Designed for Umbilical Hernia Repair
Phasixâ„¢ ST Umbilical Hernia Patch Leverages Same Surgical Technique as Permanent Mesh Procedures FRANKLIN LAKES, N.J. , April 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) and the commercial launch of Phasixâ„¢ ST Umbilical Hernia Patch, the first and only fully absorbable hernia patch on the market designed specifically for umbilical hernias.
